That patients with MASLD might have different immune responses was shown in COVID-19, where several cytokines and chemokines were linked with uncontrolled inflammation and development of severe/critical disease (such as IL-6, IL-8, IL-10, TGF-β1 and CXCL10) [19,20]. This evidence concerns the gene CXCL10 and metabolic dysfunction-associated steatotic liver disease.